Primary genotypic resistance of HIV-1 to CCR5 antagonists in CCR5 antagonist treatment-naive patients

AIDS

Volumn 22, Issue 16, 2008, Pages 2212-2214

  Soulié, Cathia ^a,b   Malet, Isabelle ^a   Lambert Niclot, Sidonie ^a,b   Tubiana, Roland ^b,c   Thévenin, Monique ^b   Simon, Anne ^b   Murphy, Robert ^a,b   Katlama, Christine ^a,b,c   Calvez, Vincent ^a,b   Marcelin, Anne Geneviève ^a,b  

^a SORBONNE UNIVERSITÉ   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 120; MARAVIROC; VICRIVIROC;

ANTIVIRAL RESISTANCE; ARTICLE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; IN VIVO STUDY; MUTATION RATE; PRIORITY JOURNAL; RECEPTOR BINDING;

CYCLOHEXANES; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV ENVELOPE PROTEIN GP120; HIV FUSION INHIBITORS; HIV-1; HUMANS; MUTATION; RECEPTORS, CCR5; TRIAZOLES;

EID: 55249097908     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328313bf9c     Document Type: Article

References (11)

1. Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 1999; 17:657-700.
2. Poveda E, Briz V, Quinones-Mateu M, Soriano V. HIV tropism: diagnostic tools and implications for disease progression and treatment with entry inhibitors. AIDS 2006; 20:1359-1367.
3. Briggs DR, Tuttle DL, Sleasman JW, Goodenow MM. Envelope V3 amino acid sequence predicts HIV-1 phenotype (co-receptor usage and tropism for macrophages). AIDS 2000; 14:2937-2939.
4. Jensen MA, Li FS, van't Wout AB, Nickle DC, Shriner D, He HX, et al. Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J Virol 2003; 77:13376-13388.
5. Fouchier RA, Groenink M, Kootstra NA, Tersmette M, Huisman HG, Miedema F, Schuitemaker H. Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J Virol 1992; 66:3183-3187.
6. Lewis M, Simpson P, Whitcomb J, Li X, Robertson DL, Westby M. Changes in V3 loop sequence associated with failure of maraviroc treatment in patients enrolled in the MOTIVATE 1 and 2 trials. 15th Conference on Retroviruses and Opportunistic Infections. Boston; 2008. Poster 871.
7. Westby M, Smith-Burchnell C, Mori J, Lewis M, Mosley M, Stockdale M, et al. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J Virol 2007; 81:2359-2371.
8. Tsibris AM, Sagar M, Gulick RM, Su Z, Hughes M, Greaves W, et al. In vivo emergence of vicriviroc resistance in an HIV-1 subtype C-infected subject. J Virol 2008; 82:8210-8214.
9. Soulie C, Derache A, Aime C, Marcelin AG, Carcelain G, Simon A, et al. Comparison of two genotypic algorithms to determine HIV-1 tropism. HIV Med 2008; 9:1-5.
10. Beerenwinkel N, Sing T, Lengauer T, Rahnenfuhrer J, Roomp K, Savenkov I, et al. Computational methods for the design of effective therapies against drug resistant HIV strains. Bioinformatics 2005; 21:3943-3950.
11. Mori J, Lewis M, Simpson P, Toma J, Huang W, Whitcomb J, et al. Characterization of maraviroc resistance in patients failing treatment with CCR5-tropic HIV-1 in MOTIVATE 1 and MOTIVATE 2. XVI International HIV Drug Resistance Workshop. Barbados; 2007. Abstract 10.